FOLD
FOLD
NASDAQ · Biotechnology

Amicus Therapeutics Inc

$14.41
-0.01 (-0.07%)
As of Mar 24, 9:55 PM ET ·
Financial Highlights (FY 2026)
Revenue
645.35M
Net Income
-27,581,416
Gross Margin
88.5%
Profit Margin
-4.3%
Rev Growth
+24.4%
D/E Ratio
1.43
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 88.5% 88.5% 66.7% 66.7%
Operating Margin 5.2% 4.7% 26.9% 26.5%
Profit Margin -4.3% -4.1% 20.2% 19.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 645.35M 518.65M 353.38M 365.56M
Gross Profit 571.14M 459.00M 235.61M 243.73M
Operating Income 33.36M 24.13M 94.98M 96.70M
Net Income -27,581,416 -19,949,589 71.26M 70.51M
Gross Margin 88.5% 88.5% 66.7% 66.7%
Operating Margin 5.2% 4.7% 26.9% 26.5%
Profit Margin -4.3% -4.1% 20.2% 19.3%
Rev Growth +24.4% +24.4% +12.1% +20.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.32B 1.32B 1.80B 2.08B
Total Equity 925.16M 925.16M 2.49B 2.72B
D/E Ratio 1.43 1.43 0.72 0.77
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 51.37M 39.22M 123.65M 129.48M
Free Cash Flow 60.51M 39.18M